Jefferies Double Upgrades Ionis Pharmaceuticals (IONS) to Buy

Jefferies analyst Akash Tewari upgraded Ionis Pharmaceuticals (NASDAQ: IONS) from Underperform to Buy with a price target of $75.00 (from $29.00).

The analyst comments "At ~$48, there's still upside for IONS. We're mainly bullish on Eplontersen in ATTR-CM (Ph.3 CARDIO-TTRansform data mid'26). We think trial reads out positively & could hit stat sig on combo (while HELIOS-B likely misses on combo) to support broader 1L uptake. Addtly, we est. IONS’s de-risked base business (incl. Spinraza, Doni & net cash) has NPV of ~$35. Finally, IONS has a diversified pipeline (eg, Olezarsen, Pelacarsen) which offers optionality. Buy, PT $75."

For an analyst ratings summary and ratings history on Ionis Pharmaceuticals click here. For more ratings news on Ionis Pharmaceuticals click here.

Shares of Ionis Pharmaceuticals closed at $47.57 yesterday.

You May Also Be Interested In

• DA Davidson Reiterates Buy Rating on Tractor Supply Company (TSCO) Amid Soft Q2 Expectations
• UBS: Micron could repurchase more than 40% of shares by 2028
• Nebius Group (NBIS) PT Raised to $410 at Northland